What is the recommended treatment for hepatitis C genotype 2?

Treatment for Hepatitis C Genotype 2

For HCV genotype 2, treat with sofosbuvir/velpatasvir 400/100mg once daily for 12 weeks regardless of cirrhosis status or treatment history, or alternatively glecaprevir/pibrentasvir for 8 weeks (non-cirrhotic) or 12 weeks (cirrhotic). 1

Preferred First-Line Regimens

The most recent guidelines establish clear hierarchies for genotype 2 treatment:

Option 1: Sofosbuvir/Velpatasvir (Preferred)

• 12 weeks for all patients - treatment-naïve, treatment-experienced, with or without cirrhosis 2, 3
• Achieves 99-100% SVR12 rates across all patient populations 1, 3
• Single-tablet regimen with excellent tolerability
• No ribavirin needed in any scenario 2

Option 2: Glecaprevir/Pibrentasvir (Co-Preferred)

• 8 weeks for non-cirrhotic patients (treatment-naïve or experienced) 1
• 12 weeks for cirrhotic patients (treatment-naïve or experienced) 1
• Achieves 99-100% SVR12 rates 1
• Meta-analysis confirms 100% SVR12 (95% CI: 99-100%) 4

Alternative Regimens (When Preferred Options Unavailable)

Sofosbuvir + Ribavirin

• Non-cirrhotic: 12 weeks with weight-based ribavirin 1, 5
• Cirrhotic: 16 weeks (treatment-naïve) or 16-24 weeks (treatment-experienced) 1, 6
• SVR rates: 95-97% in non-cirrhotic, 83-89% in cirrhotic patients 7, 8
• Important caveat: Lower efficacy in cirrhosis compared to pangenotypic regimens; extend duration to 16-20 weeks for cirrhotic patients 7, 8

Daclatasvir + Sofosbuvir

• 12 weeks for all patients (with or without cirrhosis, treatment-naïve or experienced) 1
• 100% SVR in limited real-world data 1
• Consider when ribavirin contraindicated 6

Key Clinical Considerations

Cirrhosis does NOT require treatment modification with sofosbuvir/velpatasvir or appropriately-dosed glecaprevir/pibrentasvir. The older sofosbuvir/ribavirin regimen is the only one requiring duration extension for cirrhosis 1, 8.

Treatment experience does NOT affect regimen choice - the same durations apply for treatment-naïve and treatment-experienced patients with modern DAA regimens 1, 2.

Ribavirin is unnecessary with pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir), eliminating concerns about anemia and dose reductions that occur in 20-25% of patients on ribavirin-containing regimens 9.

Common Pitfalls to Avoid

1. Don't use peginterferon-based regimens - these are outdated with SVR rates of only 63-70% and significant toxicity 6

2. Don't use ledipasvir/sofosbuvir - while some real-world data shows 96-97% SVR for genotype 2 10, 11, this is off-label use and inferior to approved pangenotypic options

3. Don't unnecessarily extend treatment - 12 weeks of sofosbuvir/velpatasvir is sufficient even for cirrhotic, treatment-experienced patients 2, 3

4. Don't add ribavirin to pangenotypic regimens - no benefit demonstrated and adds toxicity 2

Safety Profile

Both preferred regimens demonstrate excellent tolerability:

• Most common adverse events: fatigue (14%), headache (13%) 4
• Serious adverse events and treatment discontinuation are rare (<3%) 4, 10
• No significant renal function changes, even in CKD 3a/3b 11